The company said it has signed a term sheet for an option to license patent applications related to knocking down beta III-tubulin using RNAi, an approach that has been shown to sensitize cancer cells to chemotherapy.
The Yale spinout's technology involves attaching "high densities of application-specific molecules to the surfaces of biodegradable, polymeric particles ranging in size from tens of nanometers to hundreds of microns."
The transaction "provides the company with additional financial resources to fund acquisitions and support bringing [its] projects and pipeline of novel drugs and products to market," according to Opko Chairman and CEO Phillip Frost.
CEO Peter Meldrum said at a conference this week that Myriad's sales force "provides doctors [with] the tools to do counseling" in-house, and as a result, physicians can bill insurers directly for the service.
A Roche official said that a primary focus for the company is launching drug/diagnostic combination treatments through its personalized healthcare franchise, since such products are differentiated from others on the market, may go through regulatory approval faster, and justify higher pricing.
While CombiMatrix did not disclose the terms within which a recently hired investment bank will serve as its "financial and strategic advisor," such moves typically are overtures to mergers, acquisitions, or asset divestitures.
Speaking after the firm's presentation Monday at the UBS Global Life Sciences Conference, Fluidigm CFO Vikram Jog told GenomeWeb Daily News that the company still intends to go public, but the timing remains uncertain.
The USPTO said that since the co-assignees of the Tuschl-I IP “have divergent interests, no one side can reasonably expect or be permitted to control the prosecution of [the] patent application [at issue] to the exclusion of the others.”
The subsidiary will be located in San Diego, Calif., and will be led by Santaris Chief Development Office Arthur Levin, who was previously senior vice president of drug development at antisense shop Isis Pharmaceuticals.
Exiqon said that it has achieved several milestones in a collaboration with Tacere Therapeutics, including the completion of a series of customizable assays for the detection of therapeutic shRNAs currently under development through a partnership between Tacere and Pfizer.